|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 180 | Dying to Produce a Lively HIV Vaccine: HIV DNA Vaccines Improving Antigen Delivery to Dendritic Cells through Apoptosis in Vivo Results in Improved Cellular Immunity
M. A. Chattergoon, J. J. Kim, J.-S. Yang, J. I. Sin, S. Kudchodkar, and D. B. Weiner* Univ. of Pennsylvania Sch. of Med. and Viral Genomix, Philadelphia, USA |
| 181 | Enhanced Humoral Immune Responses Elicited by DNA Vaccination with HIV gp120-C3d Fusion Constructs
T. Ross*1, T. Green1, Y. Xu2, D. Montefiori3, and H. Robinson2 1East Carolina Univ., Greenville, NC, USA; 2Emory Univ., Atlanta, GA, USA; and 3Duke Univ., Durham, NC, USA |
| 182 | Enhancement of Immune Responses with a DNA Vaccine Construct That Targets APCs
W. Zhang*, Z. Chen, Y. Huang, and D. D. Ho Aaron Diamond AIDS Res. Ctr., The Rockefeller Univ., New York, NY, USA |
| 183 | Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed HIV DNA Vaccines
M. Briones*1, D. O'Hagan1 , M. Singh1, M. Ugozzoli1, C. Wild2, S. Barnett1, M. Chen1, G. R. Otten1, and J. B. Ulmer1 1Chiron Corp., Emeryville, CA, USA and 2Panacos Pharmaceuticals, Gaithersburg, MD, USA |
| 184 | HIV Gag DNA Vaccine: Mutation in the Gag Increases Its Immunogenicity
H. Zhang and L. Qiao* Loyola Univ. Chicago, Maywood, IL, USA |
| 185 | Attenuated HIV-1 nef DNA Vaccine Construct Induces Memory T-Cell Response
B. Majumdar1, B. Gray1, S. Mahalingam2, S. McBurney1, T. Schaefer1, T. Dentchev3, T. Reinhart1, and V. Ayyavoo*1 1Univ. of Pittsburgh Graduate Sch. of Publ. Hlth., PA, USA; 2Ctr. for DNA Fingerprinting and Diagnostics, Hydrabad, India; and 3Univ. of Pennsylvania, Philadelphia, USA |
| 186 | Immunological Properties of HIV-1 env Gene-Based DNA Vaccines
B. V. Murashev*, I. V. Murasheva, T. Y. Kreslavskiy, A. E. Romanovitch, N. A. Klimov, and A. P. Kozlov Biomedical Ctr., St. Petersburg, Russia |
| 186a | Prime-Boost Immunisation Leads to the Development of a Persistent, High Avidity
CD8 T-Cell Population
M. J. Estcourt1, A. Brookes2, A. J. Ramsay3, S. A. Thomson1, C. J. Medveckzy1, and I. A. Ramshaw*1 1John Curtin Sch. of Med. Res., Australian Natl. Univ., Canberra; 2Univ. of Melbourne, Australia; and 3Ctr. for Biomolecular Vaccine Technology, Univ. of Newcastle, Australia |